About the Company
Arthur D. Levinson (born March 31, 1950) is an American businessman and is the chairman of Apple Inc. (2011–present) and chief executive officer (CEO) of Calico (an Alphabet Inc. venture). He is the former CEO (1995–2009) and chairman (1999–2014) of Genentech. In addition to the board of Apple Inc. (2000–present), Levinson is on the board of directors of the Broad Institute. Previously, Levinson had been on the board of directors at Hoffmann-La Roche (2010–2014), NGM Biopharmaceuticals (2009–2014), and Amyris Biotechnologies (2009–2014). He is on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, the Industrial Advisory Board of the California Institute for Quantitative Biosciences (QB3), the advisory council for the Princeton University Department of Molecular Biology and the advisory council for the Lewis-Sigler Institute for Integrative Genomics.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NGM News
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
Investors are always looking for stocks that are poised to beat at earnings season and NGM Biopharmaceuticals, Inc. NGM may ...
NGM Bio Announces Closing of Tender Offer
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative ...
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM ... One other stock from the same industry, Aadi Bioscience, Inc. (AADI), is yet to report results for the quarter ended December 2023. The results are expected ...
NGM Biopharmaceuticals: Q4 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — NGM Biopharmaceuticals Inc. (NGM) on Monday reported a loss of $27.7 million in its fourth quarter. On a per-share basis ...
NGM Biopharmaceuticals Inc USD0.001
Atlas Neon Parent Inc and Atlas Neon Merger Sub Inc (affiliates of The Column Group LP) have made an offer to buy NGM Biopharmaceuticals Inc shares at a price of USD1.55 per share. The company ...
NGM Biopharmaceuticals, Inc.: NGM Bio Announces Closing of Tender Offer
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ("NGM Bio") (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics ...
Loading the latest forecasts...